Entera Bio scores $10 million investment to fund oral drug pipeline

Entera Bio Ltd. (Nasdaq: ENTX) secured a $10 million investment led by BVF Partners, providing a critical capital infusion to advance its platform for turning injectable peptide drugs into oral medications. The financing addresses a key challenge for the clinical-stage biotech company: funding the expensive, multi-year process of drug development.

"This investment from a leading life sciences investor like BVF is a significant validation of our technology and its potential to shift the paradigm from injections to oral delivery for a wide range of peptide-based therapies," Miranda Toledano, CEO of Entera Bio, said in a statement.

The private placement, announced on April 2, 2026, consists of 2,857,143 American Depositary Shares (ADSs) and two sets of warrants, priced at a combined $3.50 per share. The initial gross proceeds are $10 million, with the potential for up to $24.5 million if all warrants are exercised. The warrants are exercisable at $4.00 and $5.00 per share, respectively.

For a clinical-stage company like Entera, the funding extends its operational runway and de-risks the development of its pipeline, which focuses on the oral delivery of large-molecule drugs. The backing from a notable biotech investor like BVF Partners could also attract further institutional interest, a crucial factor for companies not yet generating revenue.

Advancing Oral Drug Delivery

Entera Bio's proprietary technology aims to solve a long-standing challenge in the pharmaceutical industry: the poor oral bioavailability of large-molecule drugs like peptides and proteins. These drugs are typically administered via injection, which can be a significant burden for patients with chronic conditions. Entera's platform encapsulates these molecules in a synthetic carrier that protects them from degradation in the digestive system and enhances their absorption.

The company's lead candidate, EB613, is an oral formulation of teriparatide for the treatment of osteoporosis. This new capital is expected to help advance EB613 and other pipeline programs. The success of this platform could position Entera as a key player in the drug delivery market, competing with other companies like Rani Therapeutics (NASDAQ: RANI) which is also developing an oral delivery system for biologics.

Investor Implications

The financing provides Entera with a much-needed cash runway, a key metric for investors evaluating pre-revenue biotech firms. The structure of the deal, with warrants exercisable at higher prices, suggests confidence from BVF Partners in the company's future prospects. If Entera's clinical trials show positive results, the stock could see significant upside, although clinical development is fraught with risk.

This article is for informational purposes only and does not constitute investment advice.